In 2016, the first ex vivo gene therapy worldwide, StrimvelisTM, based on hematopoietic stem cells (HSC), was approved by the EMA for the treatment of severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID) in pediatric patients that did not have an adequate cell donor [229]. Here, ADA is linked to severe combined immunodeficiency.